Homology Medicines, Inc (FIXX)

Etorro trading 970x250
Homology Medicines, Inc (FIXX) Logo

About Homology Medicines, Inc

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts. Address: One Patriots Park, Bedford, MA, United States, 01730

Homology Medicines, Inc News and around…

Latest news about Homology Medicines, Inc (FIXX) common stock and company :

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
21 Oct, 2021 Yahoo! Finance

- Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage gene therapy program for mucopolysaccharidosis type II (MPS II, or Hunter syndrome), clinical-stage gene editing program for phenylketonuria (PKU), GTx-mAb program for paroxysmal nocturnal hemoglobinuria (PNH) and assays to

Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
20 Oct, 2021 Yahoo! Finance

- Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials - BEDFORD, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations of nonclinical data and patient and caregiver feedback that support the Company’s clinical programs for mucopolysaccharidosis type II (MPS II), or Hunter syndrome, and phenylketonuria (PKU). Dur

Relative Strength Alert For Homology Medicines
18 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
18 Oct, 2021 Yahoo! Finance

- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome - BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has initiated the Phase 1 trial for HMI-203, a one-time, in vivo gene therapy candidate for the treatment of adults with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. The juMPStart trial is an open-label, dose-escalation study evaluating

Interesting FIXX Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Homology Medicines Inc (FIXX) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FIXX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares?
13 Oct, 2021 Yahoo! Finance

Every investor in Homology Medicines, Inc. ( NASDAQ:FIXX ) should be aware of the most powerful shareholder groups...

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
13 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar ...

Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
12 Oct, 2021 Yahoo! Finance

- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in Ongoing pheNIX Trial of HMI-102 Gene Therapy for Adults with PKU - BEDFORD, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the pheEDIT Phase 1 clinical trial for HMI-103, a one-time, in vivo product candidate that utilizes a gene

Implied Volatility Surging for Homology Medicines (FIXX) Stock Options
11 Oct, 2021 Yahoo! Finance

Investors need to pay close attention to Homology Medicines (FIXX) stock based on the movements in the options market lately.

The Math Shows IBB Can Go To $199
04 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Biotechnology ETF (IBB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $199.35 per unit.

Bullish Two Hundred Day Moving Average Cross - FIXX
24 Sep, 2021 FinancialContent

In trading on Friday, shares of Homology Medicines Inc (FIXX) crossed above their 200 day moving average of $8.79, changing hands as high as $8.85 per share. Homology Medicines Inc shares are currently trading up about 0.9% on the day..

12 Health Care Stocks Moving In Thursday's Pre-Market Session
23 Sep, 2021 FinancialContent

Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 23.66% to $3.24 during Thursday's pre-market ...

Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%
14 Aug, 2021 Yahoo! Finance

Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders will have a reason to smile today, with the analysts making...

Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates
12 Aug, 2021 Yahoo! Finance

Homology Medicines (FIXX) delivered earnings and revenue surprises of 6.90% and 249.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
12 Aug, 2021 FinancialContent
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board
05 Aug, 2021 FinancialContent
Homology Medicines to Participate in Upcoming Investor Conferences
04 Aug, 2021 FinancialContent
Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
02 Aug, 2021 Yahoo! Finance

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sum Up The Pieces: IBBQ Could Be Worth $32
02 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.72 per unit.

If You Had Bought Homology Medicines' (NASDAQ:FIXX) Shares Three Years Ago You Would Be Down 67%
19 Jun, 2021 Yahoo! Finance

If you love investing in stocks you're bound to buy some losers. But long term Homology Medicines, Inc. ( NASDAQ:FIXX...

Interesting FIXX Put And Call Options For August 20th
18 Jun, 2021 FinancialContent

Investors in Homology Medicines Inc (FIXX) saw new options become available this week, for the August 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FIXX options chain for the new August 20th contracts and identified one put and one call contract of particular interest.

The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
25 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Notable Monday Option Activity: IAC, FIXX, YETI
24 May, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IAC/InterActiveCorp (IAC), where a total volume of 4,313 contracts has been traded thus far today, a contract volume which is representative of approximately 431,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 70.3% of IAC's average daily trading volume over the past month, of 613,440 shares..

High Flyers At Much Lower Altitudes
14 May, 2021 FinancialContent

Stocks with extreme valuations have taken a serious haircut since the space peaked on February 22nd.

Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
13 May, 2021 FinancialContent
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
07 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Homology Medicines (FIXX) Reports Q1 Loss, Tops Revenue Estimates
06 May, 2021 Yahoo! Finance

Homology Medicines (FIXX) delivered earnings and revenue surprises of 96.92% and 3681.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
06 May, 2021 FinancialContent
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
03 May, 2021 FinancialContent
Will Homology Medicines (FIXX) Report Negative Q1 Earnings? What You Should Know
29 Apr, 2021 Yahoo! Finance

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Homology Medicines, Inc (FIXX) is a NASDAQ Common Stock listed in , ,

970x250